214 related articles for article (PubMed ID: 7334406)
21. Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability.
Rinne UK
Eur Neurol; 1987; 27 Suppl 1():120-5. PubMed ID: 3428305
[TBL] [Abstract][Full Text] [Related]
22. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
[TBL] [Abstract][Full Text] [Related]
23. Prolactin secretion in Parkinson disease.
Eisler T; Thorner MO; MacLeod RM; Kaiser DL; Calne DB
Neurology; 1981 Oct; 31(10):1356-9. PubMed ID: 6810204
[TBL] [Abstract][Full Text] [Related]
24. Clinical implications of sustained dopaminergic stimulation.
Stocchi F; Patsalos PN; Berardelli A; Barbato L; Bonamartini A; Manfredi M; Ruggieri S
Clin Neuropharmacol; 1994; 17 Suppl 2():S7-13. PubMed ID: 9358190
[TBL] [Abstract][Full Text] [Related]
25. Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
Quinn NP; Marion MH; Marsden CD
Eur Neurol; 1987; 27 Suppl 1():105-13. PubMed ID: 3322834
[TBL] [Abstract][Full Text] [Related]
26. The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
Guo G; Xu S; Cao LD; Wu QY
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2409-12. PubMed ID: 27338068
[TBL] [Abstract][Full Text] [Related]
27. Madopar HBS. International workshop on the 'on-off-phenomenon in Parkinson's disease. New possibilities for its management. Agno, November 14-16, 1985.
Eur Neurol; 1987; 27 Suppl 1():1-142. PubMed ID: 3428304
[No Abstract] [Full Text] [Related]
28. A study on the effect and tolerance of lisuride on Parkinson's disease.
Bayülkem K; Erişir K; Tuncel A; Bayülkem B
Adv Neurol; 1996; 69():519-30. PubMed ID: 8615174
[TBL] [Abstract][Full Text] [Related]
29. Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor.
Weller C; O'Neill CJ; Charlett A; Bowes SG; Purkiss A; Nicholson PW; Dobbs RJ; Dobbs SM
Br J Clin Pharmacol; 1993 Apr; 35(4):379-85. PubMed ID: 8485018
[TBL] [Abstract][Full Text] [Related]
30. Open clinical study of Madopar HBS.
Ludin HP
Eur Neurol; 1987; 27 Suppl 1():73-5. PubMed ID: 3322838
[TBL] [Abstract][Full Text] [Related]
31. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
Pezzoli G; Tesei S; Ferrante C; Cossutta E; Zecchinelli A; Scarlato G
Mov Disord; 1988; 3(1):37-45. PubMed ID: 3050471
[TBL] [Abstract][Full Text] [Related]
32. Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy.
Rondot P; Ziegler M; Aymard N; Holzer J
Eur Neurol; 1987; 27 Suppl 1():114-9. PubMed ID: 3322835
[TBL] [Abstract][Full Text] [Related]
33. The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease.
Steiger MJ; Stocchi F; Bramante L; Ruggieri S; Quinn NP
Clin Neuropharmacol; 1992 Dec; 15(6):501-4. PubMed ID: 1477849
[TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease.
Lieberman A; Estey E; Gopinathan G; Ohashi T; Sauter A; Goldstein M
Neurology; 1978 Sep; 28(9 Pt 1):964-8. PubMed ID: 567768
[TBL] [Abstract][Full Text] [Related]
35. [Efficiency of new forms of madopar in Parkinson's disease].
Vendrova MI; Sadekov RA; Golubev VL
Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(12):46-8. PubMed ID: 11195538
[TBL] [Abstract][Full Text] [Related]
36. Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
Chouza C; Romero S; de Medina O; Aljanati R; Scarmelli A; Caamano JL; Gonzales Panizza V
Eur Neurol; 1987; 27 Suppl 1():59-67. PubMed ID: 3428309
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up.
Pacchetti C; Martignoni E; Sibilla L; Bruggi P; Turla M; Nappi G
Eur Neurol; 1990; 30(6):319-23. PubMed ID: 2289507
[TBL] [Abstract][Full Text] [Related]
38. Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study.
Nordera GP; Lorizio A; Lion P; Durisotti C; D'Andrea G; Ferro-Milone F
Eur Neurol; 1987; 27 Suppl 1():76-80. PubMed ID: 3322839
[TBL] [Abstract][Full Text] [Related]
39. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
Dessibourg CA; Gachoud JP
Praxis (Bern 1994); 1995 Oct; 84(43):1235-8. PubMed ID: 7481341
[TBL] [Abstract][Full Text] [Related]
40. Levodopa with benserazide or carbidopa in Parkinson disease.
Rinne UK; Mölsä P
Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
